Philips: Philips expands network of clinical partners to set new standard of care for the early diagnosis and treatment of lung cancer

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today provided an update on the growing global clinical interest in its innovative lung cancer diagnosis and treatment solution – Philips Lung Suite – which is underlined by its rapid roll-out with new clinical partners. Some of the new innovating partner sites are: Royal Brompton Hospital – London UK; Hôpital Erasme – Brussels, Belgium; Ziekenhuis Oost-Limburg (ZOL), Genk Medical Center – Genk, Belgium; Carmel Medical Center – Haifa, Israel. Rouen University Hospital – Rouen, France is also planning to start using the innovation. Several healthcare providers have already successfully diagnosed their first patients using Lung Suite, which works in combination with the company’s Image Guided Therapy System – Azurion.



Lung cancer is the number one cause of cancer death worldwide, claiming the lives of 1.8 million people per year [1]. More than 60% of lung cancer patients are diagnosed at a late stage, reducing their odds of survival [2]. Philips Lung Suite is a revolutionary 3D real-time imaging platform that addresses the need for earlier precision diagnosis and minimally-invasive treatment with an all-in-one platform that enables doctors to perform biopsy, ablation, marking of lesions, and/or thoracic surgery procedures in the same room, allowing patients to be both diagnosed and treated. Its ability to locate and characterize small-sized lesions could significantly enhance future lung cancer care.

Philips Lung Suite has been shown to increase the accuracy of lung cancer biopsy procedures, improving results for patients and offering the potential to immediately treat early-stage lung cancer patients.
Karim Boussebaa

General Manager, Image Guided Therapy Systems at Philips


“Philips Lung Suite has been shown to increase the accuracy of lung cancer biopsy procedures, improving results for patients and offering the potential to immediately treat early-stage lung cancer patients,” said Karim Boussebaa, General Manager, Image Guided Therapy Systems at Philips. “These new partners add to our rapidly expanding global ecosystem of clinical partners who are pushing innovation forward, with of the goal of offering patients diagnosis and minimally-invasive treatment in a single procedure, improving patient outcomes and their quality of life.”